This article is more than 5 years old. Information may no longer be current.

NovaBay reports $3.6 million quarterly net loss

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NovaBay Pharmaceuticals reported a net loss of $3.6 million for the first quarter of 2014, compared with a loss of $4 million for the same period in 2013, according to a press release.

Cash, cash equivalents and short-term investments increased to $15.2 million, compared with $13.1 million in the second quarter 2013. License and collaboration revenue was $300,000, down from $1 million in the first quarter 2013.

Research and development expenses totaled $2.5 million, compared with $2.9 million in the first quarter 2013. The decrease was attributed to a reduction in clinical activities as NovaBay completes trials, including ones for viral and bacterial conjunctivitis.

General and administrative expenses totaled $1.7 million, compared with $1.6 million in the first quarter of 2013. This was attributed mainly to increased business development related to a product launch and planned commercialization of the company’s ophthalmology and dermatology business units.